Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Perineoplastic Erythroderma and Dedifferentiated Melanoma: Diagnostic Clues in Rash-to-Mass Dermatopathology
Description
The talk highlighted two dermatopathology diagnostic challenges: paraneoplastic erythroderma and dedifferentiated melanoma. In the first section, two patients presented with abrupt, treatment-refractory erythroderma with mixed spongiotic and interface dermatitis on biopsy, positive ANA testing, and no convincing clinical evidence of connective tissue disease. Extensive workups ultimately revealed underlying malignancies—a systemic marginal zone lymphoma in one patient and a poorly differentiated breast adenocarcinoma in the other—and both rashes improved when the cancers were treated, underscoring that malignancy should be considered in sudden-onset, refractory erythroderma, especially with mixed histology and unexplained systemic symptoms. In the second section, a sun-damaged skin tumor with rhabdoid morphology was initially difficult to classify because it lacked conventional melanocytic markers and also stained negative for several other lineage markers. Additional tissue and molecular/IHC workup showed focal SOX10/S100 positivity plus strong BRAF V600E and diffuse PRAME expression, supporting dedifferentiated melanoma. The speaker emphasized that these tumors can mimic sarcoma or AFX/PDS, may lose standard melanoma markers, and are often best diagnosed with molecular testing; PRAME and BRAF can be useful adjuncts, but molecular analysis remains the most definitive approach. Overall, the key message was to broaden the differential for abrupt rash and to use molecular tools early when evaluating undifferentiated cutaneous tumors.
View moreConclusions
- Abrupt-onset, treatment-refractory erythroderma with a mixed spongiotic and interface dermatitis pattern should raise concern for a paraneoplastic process, especially in older patients.
- A positive ANA in a rash without convincing connective-tissue disease features or histologic mucin can be a misleading clue and should prompt malignancy evaluation.
- Both systemic lymphoma and breast carcinoma can present with paraneoplastic erythroderma, and the skin disease may improve when the underlying cancer is treated.
- Undifferentiated or dedifferentiated melanoma can closely mimic sarcoma or other poorly differentiated cutaneous tumors and may lose all conventional melanocytic markers.
- Molecular testing remains the most important tool for diagnosing immunohistochemically unclassifiable cutaneous tumors, and it can reclassify a meaningful fraction as melanoma.
- PRAME is the most sensitive immunostain for dedifferentiated melanoma, but it is not specific and must be interpreted with caution.
- BRAF immunohistochemistry and molecular driver analysis are especially helpful adjuncts in suspected dedifferentiated melanoma and may identify actionable targets earlier.
- The best diagnostic approach is to combine morphology, selective immunostains, and molecular studies rather than relying on a limited immunohistochemical panel alone.
- Ernst M, Lundgren M, Evans MD, Miller D, Giubellino A. The mixed spongiotic and interface reaction pattern: A study of clinical and histopathologic findings. J Cutan Pathol. 2022 Aug 18;49(12):1051-1059.#10.1111/cup.14306
- Histopathology. 2022. 80, 135-149.
- Mod Path. 2019 Mar, 32(3):330-337.
- Am J Dermatopathol. 2017 Aug;39(8):593-598.
- Molecular Analysis of Cutaneous Sarcomatoid Neoplasms Frequently Identifies Melanoma Driver Variants. Am J Surg Pathol. 2025;49(7):650-657. DOI: 10.1097/PAS.0000000000002390.#10.1097/PAS.0000000000002390
- Int J Mol Sci. 2023 Jun 10;24(12):9985.
- Dermatopathology 2022, 9, 148–157.
- Virchows Arch. 2023 Aug;483(2):145-156.